Roche Accutane Updated Labeling Includes Musculoskeletal AE Warning
Executive Summary
Roche is updating Accutane labeling with a warning on potential musculoskeletal adverse effects, particularly in adolescents
You may also be interested in...
Accutane Labeling Revised To Include Psychiatric Disorder Brochure
Labeling for Roche's Accutane has been revised to include a brochure for isotretinoin prescribers on recognizing and appropriately handling psychiatric disorders
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials